Revenue
2019
2020
2021
2022
2023
NovaBridge Biosciences (NBP)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | $632,000 | −$1.6M | $13.8M | $236.4M | $4.3M |
| Research & development | $62.9M | $21.8M | $21.4M | $22.5M | $190.3M | $150.9M | $120.7M |
| Operating expenses | $94.3M | $51.4M | $72.6M | $51.5M | — | — | — |
| Operating income | −$94.3M | −$51.4M | −$72.0M | −$53.1M | — | — | — |
| EBITDAderived | — | −$51.1M | −$71.5M | −$52.9M | — | — | — |
| Net income | −$46.3M | −$22.2M | −$207.7M | −$371.1M | −$365.9M | $72.2M | −$208.6M |
| Basic EPSper diluted share | -$0.21 | -$0.12 | -$1.09 | -$1.96 | -$2.09 | $0.54 | -$28.90 |
| Diluted EPSper diluted share | -$0.21 | -$0.12 | -$1.09 | -$1.96 | -$2.09 | $0.46 | -$28.90 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 18, 2026Form 4 | Dennis Phillip AndrewChief Medical Officer | SellOrdinary Shares | 8.5K | $0.66 | $5.6K | 157.9K |
| Jun 1, 2026Form 4 | Xu Cong ClaireSVP, Clinical Development | SellOrdinary Shares | 3.5K | $3.94 | $13.8K | 290.2K |
| May 14, 2026Form 4 | Cao Sean WuxiongSee Remarks | SellOrdinary Shares | 21.4K | $1.99 | $42.6K | 35.1K |
| Apr 24, 2026Form 4 | Hagler Mark ArnoldSee Remarks | BuyOrdinary Shares | 230.0K | $2.51 | $577.3K | 230.0K |